Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ENDP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Endo International plc and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 12, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Endo International plc("Endo" or the "Company") (NASDAQ:ENDP). Investors who purchased Endo securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/endp.

The investigation concerns whether Endo and certain of its officers and/or directors have violated federal securities laws.

On June 10, 2020, the New York Department of Financial Services ("DFS") issued a press release announcing that it "has filed charges and initiated administrative proceedings against Endo International plc and its subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals, Inc., and Par Pharmaceutical Companies, Inc." in connection with "DFS' ongoing investigation into the entities that created and perpetuated the opioid crisis." The DFS press release stated that "[t]he DFS' statement of charges alleges that, like other opioid Manufactures, Endo . . . [k]nowingly furthered a false narrative to legitimize opioids as appropriate for broad treatment of pain by downplaying their long-known addictive nature and risks"; "[m]isrepresented the safety and efficacy of opioids, without legitimate scientific substantiation"; and "[d]eployed a large sales force to target healthcare providers directly with these misrepresentations." Following the DFS announcement, Endo's stock price fell sharply, damaging investors.

If you are aware of any facts relating to this investigation, or purchased Endo shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/endp. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/593774/ENDP-Investor-Alert-Bronstein-Gewirtz-Grossman-LLC-Announces-Investigation-of-Endo-International-plc-and-Encourages-Investors-to-Contact-the-Firm



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today